NSE: PPLPHARMA | BSE: 543635

Momentum Trap

Download real time

171.14 -0.79 (-0.46%)

29.36% Gain from 52W Low

1.6M NSE+BSE Volume

NSE 15 Jul, 2026 1:29 PM (IST)

22,784.7

Market Cap

High in industry

Beta 1Year

High Volatility

Piramal Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PPLPHARMA, BSE:543635 Piramal Pharma Ltd.

Search Inside the pdf :

Piramal Pharma Ltd.

30 Apr 2026

171.14

-0.46%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

Normalisation expected from FY27- Overall performance was largely in line with expectations. The CDMO business was impacted by de-stocking; adjusting for this, the segment delivered healthy double-digit revenue growth in Q4. Improving biopharma funding is also translating into stronger RFP momentum and a pickup in order inflows for the CDMO segment. Management is also focusing on Cost Optimization & Operational Excellence which should help improve profitability of the segment going forward. The CHG business was affected by the postponement of certain...

Piramal Pharma Ltd. is trading below its 200 day SMA of 171.2

Piramal Pharma Ltd.

29 Apr 2026

171.14

-0.46%

Operationally below est.; ends FY26 on a weak note

Buy: Piramal Pharma Ltd.

Motilal Oswal

Piramal Pharma (PIRPHARM) posted in-line revenue for 4QFY26. The EBITDA was lower than expected (an 8% miss), primarily due to a product mix change.

Piramal Pharma Ltd. is trading above its 150 day SMA of 163.1

Piramal Pharma Ltd.

30 Jan 2026

171.14

-0.46%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

PPL owns 17 development and manufacturing facilities across India, US and UK with capabilities in sterile, API, formulations, drug discovery and manufacturing of nutrition products. The company holds 49% stake in AbbVie Therapeutics, JV with...

Number of FII/FPI investors decreased from 244 to 231 in Mar 2026 qtr

Piramal Pharma Ltd.

29 Jan 2026

171.14

-0.46%

3Q below estimates; trough phase extends

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma posted a miss on revenue/EBITDA in 3QFY26, affected by low traction in CDMO business. Complex hospital generics (CHG) business was largely stable YoY, with regulatory delays keeping growth in check.

Piramal Pharma Ltd. has an average target of 225.00 from 3 brokers.

Piramal Pharma Ltd.

06 Nov 2025

171.14

-0.46%

2Q – A miss; higher opex drags earnings

Buy: Piramal Pharma Ltd.

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered in-line revenue for 2QFY62. However, it delivered a miss on EBITDA/PAT for the quarter. Higher operational costs impacted the quarter’s performance.

Piramal Pharma Ltd. is trading below its 200 day SMA of 171.2

Piramal Pharma Ltd.

29 Jul 2025

171.14

-0.46%

Near-term weak due to the muted CHG business

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) exhibited lower-than-expected financial performance in 1QFY26. Lower CDMO and complex hospital generics (CHG) sales led to a considerable operating deleverage.

Piramal Pharma Ltd. is trading below its 200 day SMA of 171.2

Piramal Pharma Ltd.

29 Jul 2025

171.14

-0.46%

Temporary slowdown before a sprint

Buy: Piramal Pharma Ltd.

Target

ICICI Securities Limited

Piramal Pharma’s (Piramal) Q1FY26 result was below our expectations. Performance was impacted due to lack of revenue from a large innovative CDMO (-5.7% YoY) molecule and delay in shipment timing in CHG business (grew 1%).

Piramal Pharma Ltd. is trading below its 200 day SMA of 171.2

Piramal Pharma Ltd.

15 May 2025, 12:00AM

171.14

-0.46%

Operationally, in-line 4Q; FY25 ends on a strong note

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered in-line sales/EBITDA in 4QFY25. However, its earnings were below our estimate due to impairment of certain intangible assets during the quarter.

Piramal Pharma Ltd. is trading below its 200 day SMA of 171.2

Piramal Pharma Ltd.

30 Jan 2025

171.14

-0.46%

Piramal Pharma | Q3FY25 Result Update

Buy: Piramal Pharma Ltd.

Target

Edelweiss

CDMO business to drive growth

Piramal Pharma Ltd. is trading below its 200 day SMA of 171.2

Piramal Pharma Ltd.

24 Oct 2024

171.14

-0.46%

Operating performance above est.; FY25 guidance intact

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered better-than-expected operational performance in 2QFY25 fueled by superior traction in the CDMO segment (59% of sales). Following earnings deterioration in FY23/FY24, PIRPHARM is exhibiting healthy recovery in 1HFY25.

Piramal Pharma Ltd. is trading above its 150 day SMA of 163.1

VOTE: Is Piramal Pharma Ltd. worth buying?

407 Votes:

Buy 83.05%

Sell 10.81%

Hold 6.14%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf